It’s a dogs life for PharmAust

Man’s best friend may soon owe a collective debt of gratitude to listed Perth Biotech PharmAust, if their dog cancer drug trial is successful.

PharmAust are about to commence a clinical trial of their dog cancer drug “PPL-1”  by administering increasing doses to dogs that have cancer.

To-date, 4 dogs with untreatable tumours have been administered with the drug on a compassionate basis with no discernible side effects.

PharmAust have now developed a tasteless, soft gel formula drug which makes the product more palatable for dogs as the company seeks to enter the growing $550 million dollar pet cancer market in the US where there are estimated to be over 75 million pet dogs.

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
49 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer